[[Sertindole]]

CATEGORIES: Atypical antipsychotics, Indoles, Withdrawn drugs, Piperidines, Organochlorides, Organofluorides, Ureas, Imidazolidinones

Sertindole (brand names: Serdolect, and Serlect) is an antipsychotic medication. Sertindole was developed by the Danish pharmaceutical company H. Lundbeck and marketed under license by Abbott Labs. Like other atypical antipsychotics, it has activity at dopamine and serotonin receptors in the brain. It is used in the treatment of schizophrenia. It is classified chemically as a phenylindole derivative.
Sertindole is not approved for use in the United States.

==Medical Uses==

Sertindole appears effective as an antipsychotic in schizophrenia.[tpl]cite journal|last=Lewis|first=R|coauthors=Bagnall, AM; Leitner, M|title=Sertindole for schizophrenia.|journal=Cochrane database of systematic reviews (Online)|date=Jul 20, 2005|issue=3|pages=CD001715|pmid=16034864[/tpl]

==Adverse Effects==

Very common (>10% incidence) adverse effects include:[tpl]cite web|title=PRODUCT INFORMATION SERDOLECT® TABLETS|work=TGA eBusiness Services|publisher=Lundbeck Australia Pty Ltd|date=16 January 2013|accessdate=27 October 2013|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07697-3|format=PDF[/tpl]
Common (1-10% incidence) adverse effects include:
Uncommon (0.1-1% incidence) adverse effects include:
Rare (Unknown frequency adverse events include:

==Pharmacology==

==Safety and status==

===USA===

Abbott Labs first applied for U.S. Food and Drug Administration (FDA) approval for sertindole in 1996,Zeneca's Seroquel Nears Market Approval - The Pharma Letter, 16 July 1997 but withdrew this application in 1998 following concerns over the increased risk of sudden death from QTc prolongation.Abbott Labs Withdraws Sertindole NDA Sertindole - The Pharma Letter, 12 Jan 1998 In a trial of 2000 patients on taking sertindole, 27 patients died unexpectedly, including 13 sudden deaths.[tpl]cite web |url=http://apps.who.int/medicinedocs/en/d/Js2256e/1.12.html#Js2256e.1.12 |title=WHO Pharmaceuticals Newsletter 1998, No. 03&04: Regulatory actions: Sertindole - approval application withdrawn |format= |work= |accessdate=[/tpl]  Lundbeck cites the results of the Sertindole Cohort Prospective (SCoP) study of 10,000 patients to support its claim that although sertindole does increase the QTc interval, this is not associated with increased rates of cardiac arrhythmias, and that patients on sertindole had the same overall mortality rate as those on risperidone.FDA Advisory Committee provides opinion on Serdolect for the treatment of schizophrenia - Lundbeck press release, 8 Apr 2009 Nevertheless in April 2009 an FDA advisory panel voted 13-0 that sertindole was effective in the treatment of schizophrenia but 12-1 that it had not been shown to be acceptably safe.Food and Drug Administration; Minutes of the Psychphamacological Drugs Advisory Committee, 7 Apr 2009 [tpl]Asof|October 2010[/tpl], the drug has not been approved by the FDA for use in the USA.http://www.serdolect.com

===Europe===

In Europe, sertindole was approved and marketed in 19 countries from 1996, but its marketing authorization was suspended by the European Medicines Agency in 1998EU CHMP recommends lifting ban on atypical antipsychotic Serdolect (sertindole) - National electronic Library for Medicines, NHS   and the drug was withdrawn from the market. In 2002, based on new data, the EMA's CHMP suggested that Sertindole could be reintroduced for restricted use in clinical trials, with strong safeguards including extensive contraindications and warnings for patients at risk of cardiac dysrhythmias, a recommended reduction in maximum dose from 24 mg to 20 mg in all but exceptional cases, and extensive ECG monitoring requirement before and during treatment.COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS OPINION FOLLOWING AN ARTICLE 36 REFERRAL: SERTINDOLE - European Medicines Agency, 13 Sep 2002Restricted re-introduction of the atypical antipsychotic sertindole (Serdolect) - MHRA, 2002

==References==


